Freshworks to Replace BioLife Solutions in S&P SmallCap 600

S&P Dow Jones Indices announced Freshworks (FRSH) will replace BioLife Solutions (BLFS) in the S&P SmallCap 600 on October 8, 2026. Repligen (RGN) is acquiring BioLife for $1.5B, with BioLife shareholders receiving $11.25 per share in cash and 0.1442 shares of Repligen stock. Freshworks reported Q2 2026 revenue of $237.4M, up 16% YoY, and its first GAAP profitability in 2026.

Original reporting
Published Oct 5, 2026, 10:48 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 1:58 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMergers & acquisitions
Primary signal
$FRSH
Bullish
high confidence
Mentioned
$FRSH · $RGEN · $BLFS
Relevance
8/10
AlphAI data visualization · based on securities.io
Decision brief

The 30-second read

$FRSHBullishHigh
01

Why it matters

The index addition adds passive demand for Freshworks, while the acquisition creates upside for Repligen and sets a clear valuation for BioLife.

02

Market read

Three U.S. listed companies are directly affected by index rebalancing and a sizable M&A deal, offering clear trading opportunities.

03

What to watch

Potential integration risks for Repligen and the cash drain from the $1.5 billion deal.

Relevance 8/10Novelty 8/10Timing: effective pre‑market Oct 8, 2026

Background

S&P Dow Jones announced index changes and Repligen disclosed a $1.5 billion acquisition of BioLife, with detailed terms and expected synergies.

Company-level read

Ticker impact

$FRSHBullishHigh confidence
Context

Freshworks will be added to the S&P SmallCap 600 on Oct 8, likely boosting demand from index funds.

Expected impact

likely upward as passive buying commences

Evidence & confidence

Index inclusion drives automatic buying and visibility.

$RGENBullishHigh confidence
Context

Repligen announced a definitive agreement to acquire BioLife for $1.5 billion, a material M&A transaction.

Expected impact

upward pressure from premium and expected earnings accretion

Evidence & confidence

Deal adds cash and stock consideration, with synergies and EPS accretion.

$BLFSNeutralHigh confidence
Context

BioLife is being acquired by Repligen and will be removed from the S&P SmallCap 600.

Expected impact

price will align with deal consideration

Evidence & confidence

Acquisition terms set a clear valuation floor.

Market effects

IT sector gains exposure to Freshworks; biotech/healthcare sees consolidation via Repligen‑BioLife.

U.S. small‑cap indices adjust composition; modest impact on broader market.

Limited to U.S. equity markets; no direct global macro effect.

Counterpoint

If the acquisition faces regulatory delays, RGEN could see short‑term volatility.

Key entities

  • Freshworks Inc.

    Software SaaS provider added to S&P SmallCap 600.

  • Repligen Corp.

    Biotech firm acquiring BioLife for $1.5 billion.

  • BioLife Solutions Inc.

    Target of Repligen acquisition, removed from index.

Related articles

$FRSHMed

Oppenheimer maintains Perform on Freshworks stock after Q3 results

Oppenheimer kept a Perform rating on Freshworks (NASDAQ:FRSH) after its Q3 results. The company showed improved profitability and operational efficiency, with an 85% gross profit margin over the last year. However, growth indicators were limited, and billings showed softness. Freshworks beat earnings and revenue estimates, but the stock fell in after-hours trading due to concerns about near-term growth. Needham maintained a Buy rating with a $15 price target.

$FRSHHighAI 8/10

Freshworks Inc (FRSH) Q3 2026 Earnings Call Highlights: Total ARR Tops $1 Billion

Freshworks Inc (FRSH) reported Q3 2026 revenue of $245.4M (up 14% YoY) and non-GAAP operating margin of 30%, exceeding estimates. EX ARR grew 22% YoY to $588M, driven by upmarket momentum. AI adoption accelerated, with active Copilot agents doubling YoY. Free cash flow reached $73.9M (30% margin). CX ARR growth slowed to 4% YoY, reflecting a focus on profitability. Strategic acquisitions (Torii, Robusta) added AI capabilities.

$FRSHHighAI 9/10

What Freshworks (FRSH) Said on Its Q3 Earnings Call

Freshworks (FRSH) reported Q3 earnings, highlighting a 35% YoY increase in multi-product deals and 50% growth in associated ARR. The company launched Freshservice ITAM, adding 400+ customers. Acquisitions of Torii and Robusta are expected to contribute $8M-$10M in ARR by Q4. Freshworks raised its full-year 2026 revenue outlook to $965M-$966M, with non-GAAP EPS of $0.71. The company ended Q3 with $697M in cash and no debt, repurchasing 2.7M shares for $27M.